H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Enlivex Therapeutics (ENLV) to $20 from $13 and keeps a Buy rating on the shares. The company’s debt financing is complete and provides resources to conduct Allocetra clinical development, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Highlights Rain’s AI Agent Launch and $5 Million Grant Program to Expand Prediction Markets
- Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains
- Crypto Currents: NYSE tokenization tests SEC and CFTC’s new crypto line
- Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback
- Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis